Sameer Ahmad Guru

Dr. Sameer Ahmad Guru

Luriechildrens Hospital, Northwestern University, Chicago, Illinois, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 April 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
ADAbhishek Dubey
Abhishek Dubey
GKGarima Kotnala
Garima Kotnala
TMTUHIN KUMAR MANDAL
TUHIN KUMAR MANDAL
Subash Chandra SonkarSubash Chandra Sonkar
Subash Chandra Sonkar
VSVijay K. Singh
Vijay K. Singh
BKBidhan C. Koner
Bidhan C. Koner
The present study was conducted from July 1, 2020 to September 25, 2020 in a dedicated coronavirus disease 2019 (COVID‐19) hospital in Delhi, India to provide evidence for the presence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) virus in atmospheric air and surfaces of the hospital wards. Swabs from hospital surfaces (patient's bed, ward floor, and nursing stations area) and suspended particulate matter in ambient air were collected by a portable air sampler from the medicine ward, intensive care unit, and emergency ward admitting COVID‐19 patients. By performing reverse‐transcriptase polymerase chain reaction (RT‐PCR) for E‐gene and RdRp gene, SARS‐CoV‐2 virus was detected from hospital surfaces and particulate matters from the ambient air of various wards collected at 1 and 3‐m distance from active COVID‐19 patients. The presence of the virus in the air beyond a 1‐m distance from the patients and surfaces of the hospital indicates that the SARS‐CoV‐2 virus has the potential to be transmitted by airborne and surface routes from COVID‐19 patients to health‐care workers working in COVID‐19 dedicated hospital. This warrants that precautions against airborne and surface transmission of COVID‐19 in the community should be taken when markets, industries, educational institutions, and so on, reopen for normal activities.

19 October 2021 in Biology
Verified
Journal Article
Open access
PDF file
SRShruti Rastogi
Shruti Rastogi
VKVivekananda Kalaiselvan
Vivekananda Kalaiselvan
SASher Ali
Sher Ali
AAAjaz Ahmad
Ajaz Ahmad
Sameer Ahmad GuruSameer Ahmad Guru
Sameer Ahmad Guru
MSMaryam Sarwat
Maryam Sarwat
Background: The aim of this review and meta-analysis was to identify, assess, meta-analyze and summarize the comparative effectiveness and safety of filgrastim in head-to-head trials with placebo/no treatment, pegfilgrastim (and biosimilar filgrastim to update advances in the field. Methods: The preferred reporting items for systematic reviews and meta-analyses PRISMA statement were applied, and a random-effect model was used. Primary endpoints were the rate and duration of grade 3 or 4 neutropenia, and an incidence rate of febrile neutropenia. Secondary endpoints were time to absolute neutrophil count ANC recovery, depth of ANC nadir (lowest ANC), neutropenia-related hospitalization and other neutropenia-related complications. For filgrastim versus biosimilar filgrastim comparison, the primary efficacy endpoint was the mean difference in duration of severe neutropenia DSN. Results: A total of 56 studies were considered that included data from 13,058 cancer patients. The risk of febrile neutropenia in filgrastim versus placebo/no treatment was not statistically different. The risk ratio for febrile neutropenia was 0.58, a 42% reduction in favor of filgrastim. The most reported adverse event with FIL was bone pain. For pegfilgrastim versus filgrastim, no statistically significant difference was noted. The risk ratio was 0.90 (95% CI 0.67 to 1.12). The overall difference in duration of severe neutropenia between filgrastim and biosimilar filgrastim was not statistically significant. The risk ratio was 1.03 (95% CI 0.93 to 1.13). Conclusions: Filgrastim was effective and safe in reducing febrile neutropenia and related complications, compared to placebo/no treatment. No notable differences were found between pegfilgrastim and filgrastim in terms of efficacy and safety. However, a similar efficacy profile was observed with FIL and its biosimilars.

24 February 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
RMR. Maheswari
R. Maheswari
AUAadithya B. Urs
Aadithya B. Urs
PKPriya Kumar
Priya Kumar
BKB. C. Koner
B. C. Koner
Sameer Ahmad GuruSameer Ahmad Guru
Sameer Ahmad Guru
GRGarima Rawat
Garima Rawat

19 May 2020 in Human Cell
Verified
Journal Article
Closed access
PDF file
Sameer Ahmad GuruSameer Ahmad Guru
Sameer Ahmad Guru
MSMamta P. Sumi
Mamta P. Sumi
RMRashid Mir
Rashid Mir
AWAjaz Ahmad Waza
Ajaz Ahmad Waza
MBMusadiq Ahmad Bhat
Musadiq Ahmad Bhat
ASAlpana Saxena
Alpana Saxena

1 December 2014 in Clinical Ovarian and Other Gynecologic Cancer
Verified
Journal Article
Open access
MZMariyam Zuberi
Mariyam Zuberi
RMRashid Mir
Rashid Mir
SDSagar Dholariya
Sagar Dholariya
INImtiyaz Najar
Imtiyaz Najar
PYPrasant Yadav
Prasant Yadav
ASAlpana Saxena
Alpana Saxena
BackgroundTo investigate the methylation pattern in promoter region of RASSF1A and PTEN genes in epithelial ovarian cancer patients in North India.Patients and MethodsFifty patients and 20 healthy controls were studied. Isolation of genomic DNA from peripheral blood and methylation-specific polymerase chain reaction (MSP) were applied for analysis.Results17 of 50 patients (34.0%) were found to be methylated for RASSF1A gene, whereas methylation of the PTEN gene occurred in 8 of 50 cases (16.0%). A statistically significant result was obtained (P = .01) for RASSF1A gene and correlated with the patients' clinicopathologic features.ConclusionHypermethylation of both RASSF1A and PTEN genes in blood DNA from ovarian cancer patients might offer an exposition for early diagnosis of the malignancy